Q-code: Temporary codes Temporary codes
644 codes
Billing context
Q-codes are temporary national codes recognized by Medicare. For drugs they include biosimilar products (Q51xx) and other drugs, biologicals, and skin substitutes that are not yet assigned a permanent code. Units follow the dosage in the descriptor.
| Code | Long descriptor | Payment limit (Q4 2026) | Added | Status |
|---|---|---|---|---|
| Q0035 | Cardiokymography | — | Jan 1, 1989 | Active |
| Q0081 | Infusion therapy, using other than chemotherapeutic drugs, per visit | — | Jan 1, 1992 | Active |
| Q0083 | Chemotherapy administration by other than infusion technique only (e.g., subcutaneous, intramuscular, push), per visit | — | Jan 1, 1992 | Active |
| Q0084 | Chemotherapy administration by infusion technique only, per visit | — | Jan 1, 1992 | Active |
| Q0085 | Chemotherapy administration by both infusion technique and other technique(s) (e.g., subcutaneous, intramuscular, push), per visit | — | Jan 1, 1992 | Active |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | — | Jan 1, 1992 | Active |
| Q0092 | Set-up portable x-ray equipment | — | Jan 1, 1993 | Active |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | — | Jan 1, 1994 | Active |
| Q0112 | All potassium hydroxide (koh) preparations | — | Jan 1, 1994 | Active |
| Q0113 | Pinworm examinations | — | Jan 1, 1994 | Active |
| Q0114 | Fern test | — | Jan 1, 1994 | Active |
| Q0115 | Post-coital direct, qualitative examinations of vaginal or cervical mucous | — | Jan 1, 1994 | Active |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | $0.331per 1 MG | Jan 1, 2010 | Active |
| Q0139 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis) | $0.331per 1 MG | Jan 1, 2010 | Active |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | — | Jul 1, 1996 | Active |
| Q0155 | Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | — | Jan 1, 2025 | Active |
| Q0161 | Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | — | Jan 1, 2014 | Active |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | $0.016per 1 MG | Jan 1, 2012 | Active |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | — | Apr 1, 1998 | Active |
| Q0164 | Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | — | Apr 1, 1998 | Active |
| Q0166 | Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen | $0.774per 1 MG | Apr 1, 1998 | Active |
| Q0167 | Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | $2.092per 2.5 MG | Apr 1, 1998 | Active |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | — | Apr 1, 1998 | Active |
| Q0173 | Trimethobenzamide hydrochloride, 250 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | — | Apr 1, 1998 | Active |
| Q0174 | Thiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | — | Apr 1, 1998 | Ended Dec 31, 2025 |
| Q0175 | Perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | — | Apr 1, 1998 | Active |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | — | Apr 1, 1998 | Active |
| Q0180 | Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen | — | Apr 1, 1998 | Active |
| Q0181 | Unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimenNOC / NOS | — | Apr 1, 1998 | Active |
| Q0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg | — | Dec 8, 2021 | Ended Dec 12, 2024 |
| Q0221 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg | — | Feb 24, 2022 | Ended Dec 12, 2024 |
| Q0222 | Injection, bebtelovimab, 175 mg | — | Feb 11, 2022 | Ended Dec 12, 2024 |
| Q0224 | Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg | $7,615.200per 4500 MG | Mar 22, 2024 | Active |
| Q0234 | Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg | $6.327per 1 MG | Jul 1, 2026 | Active |
| Q0235 | Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg | — | Oct 1, 2025 | Active |
| Q0237 | Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg | $4.920per 1 MG | Jan 24, 2025 | Active |
| Q0238 | Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg | $5.581per 1 MG | Apr 1, 2026 | Active |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | — | Nov 9, 2020 | Ended Apr 16, 2021 |
| Q0240 | Injection, casirivimab and imdevimab, 600 mg | — | Jul 30, 2021 | Ended Dec 12, 2024 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | — | Nov 21, 2020 | Ended Dec 12, 2024 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | — | Jun 3, 2021 | Ended Dec 12, 2024 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | — | Feb 9, 2021 | Ended Dec 13, 2023 |
| Q0247 | Injection, sotrovimab, 500 mg | — | May 26, 2021 | Ended Dec 12, 2024 |
| Q0249 | Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg | $7.569per 1 MG | Jun 24, 2021 | Active |
| Q0477 | Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only | — | Jan 1, 2018 | Active |
| Q0478 | Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type | — | Jan 1, 2011 | Active |
| Q0479 | Power module for use with electric or electric/pneumatic ventricular assist device, replacement only | — | Jan 1, 2011 | Active |
| Q0480 | Driver for use with pneumatic ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0481 | Microprocessor control unit for use with electric ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0482 | Microprocessor control unit for use with electric/pneumatic combination ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0483 | Monitor/display module for use with electric ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0484 | Monitor/display module for use with electric or electric/pneumatic ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0485 | Monitor control cable for use with electric ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0486 | Monitor control cable for use with electric/pneumatic ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0487 | Leads (pneumatic/electrical) for use with any type electric/pneumatic ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0488 | Power pack base for use with electric ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0489 | Power pack base for use with electric/pneumatic ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0490 | Emergency power source for use with electric ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0491 | Emergency power source for use with electric/pneumatic ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0492 | Emergency power supply cable for use with electric ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0493 | Emergency power supply cable for use with electric/pneumatic ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0494 | Emergency hand pump for use with electric or electric/pneumatic ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0495 | Battery/power pack charger for use with electric or electric/pneumatic ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0496 | Battery, other than lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0497 | Battery clips for use with electric or electric/pneumatic ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0498 | Holster for use with electric or electric/pneumatic ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0499 | Belt/vest/bag for use to carry external peripheral components of any type ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0500 | Filters for use with electric or electric/pneumatic ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0501 | Shower cover for use with electric or electric/pneumatic ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0502 | Mobility cart for pneumatic ventricular assist device, replacement only | — | Oct 1, 2005 | Active |
| Q0503 | Battery for pneumatic ventricular assist device, replacement only, each | — | Oct 1, 2005 | Active |
| Q0504 | Power adapter for pneumatic ventricular assist device, replacement only, vehicle type | — | Oct 1, 2005 | Active |
| Q0506 | Battery, lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only | — | Jan 1, 2010 | Active |
| Q0507 | Miscellaneous supply or accessory for use with an external ventricular assist deviceNOC / NOS | — | Apr 1, 2013 | Active |
| Q0508 | Miscellaneous supply or accessory for use with an implanted ventricular assist deviceNOC / NOS | — | Apr 1, 2013 | Active |
| Q0509 | Miscellaneous supply or accessory for use with any implanted ventricular assist device for which payment was not made under medicare part aNOC / NOS | — | Apr 1, 2013 | Active |
| Q0510 | Pharmacy supply fee for initial immunosuppressive drug(s), first month following transplant | — | Jan 1, 2006 | Active |
| Q0511 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period | — | Jan 1, 2006 | Active |
| Q0512 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period | — | Jan 1, 2006 | Active |
| Q0513 | Pharmacy dispensing fee for inhalation drug(s); per 30 days | — | Jan 1, 2006 | Active |
| Q0514 | Pharmacy dispensing fee for inhalation drug(s); per 90 days | — | Jan 1, 2006 | Active |
| Q0515 | Injection, sermorelin acetate, 1 microgram | — | Jan 1, 2006 | Active |
| Q0516 | Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 30-days | — | Jan 2, 2024 | Ended Dec 31, 2024 |
| Q0517 | Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-days | — | Jan 2, 2024 | Ended Dec 31, 2024 |
| Q0518 | Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 90-days | — | Jan 2, 2024 | Ended Dec 31, 2024 |
| Q0519 | Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 30-days | — | Sep 15, 2024 | Ended Dec 31, 2024 |
| Q0520 | Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription injectable drug, per 60-days | — | Sep 15, 2024 | Ended Dec 31, 2024 |
| Q0521 | Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription | — | Jan 1, 2025 | Active |
| Q1004 | New technology intraocular lens category 4 as defined in federal register notice | — | Jul 1, 1999 | Active |
| Q1005 | New technology intraocular lens category 5 as defined in federal register notice | — | Jul 1, 1999 | Active |
| Q2004 | Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml | — | Jul 1, 2000 | Active |
| Q2009 | Injection, fosphenytoin, 50 mg phenytoin equivalent | — | Jul 1, 2000 | Active |
| Q2017 | Injection, teniposide, 50 mg | — | Jul 1, 2000 | Ended Dec 31, 2025 |
| Q2026 | Injection, radiesse, 0.1 ml | — | Jul 1, 2010 | Active |
| Q2028 | Injection, sculptra, 0.5 mg | — | Jan 1, 2014 | Active |
| Q2034 | Influenza virus vaccine, split virus, for intramuscular use (agriflu) | — | Jul 1, 2012 | Active |
| Q2035 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria) | — | Jan 1, 2011 | Active |
| Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | — | Jan 1, 2011 | Active |
| Q2037 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | — | Jan 1, 2011 | Active |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | — | Jan 1, 2011 | Active |